Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:18 PM
Ignite Modification Date:
2025-12-24 @ 5:18 PM
NCT ID:
NCT04602650
Eligibility Criteria:
Inclusion Criteria:
Type 2 Diabetic Inclusion Criteria
1. Male or female with a diagnosis of type 2 diabetes.
2. Ages 50 to 70 years.
3. Mexican descent living in Texas.
4. Participant is willing and able to give informed consent for participation in the study.
Non-Diabetic Control Inclusion Criteria
1. Male or female without history of type 2 diabetes.
2. Ages 50 to 70 years.
3. Mexican descent living in Texas.
4. Participant is willing and able to give informed consent for participation in the study.
Exclusion Criteria:
Type 2 Diabetic Exclusion Criteria
1. Hypertension that is not controlled by greater than 2 medications.
2. Chronic kidney disease, CKD greater than 3.
3. History of coronary bypass or stint placement.
4. Current pregnancy.
5. Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease.
6. Other medical condition or medication administration deemed exclusionary by the study investigators.
Non-Diabetic Control Exclusion Criteria
1. Hypertension that is not controlled by greater than 2 medications.
2. Chronic kidney disease, CKD greater than 3.
3. History of coronary bypass or stint placement.
4. Current pregnancy.
5. Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease.
6. Other medical condition or medication administration deemed exclusionary by the study investigators.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
50 Years
Maximum Age:
70 Years
Study:
NCT04602650
Study Brief:
Protocol Section:
NCT04602650